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Dr Henrik Sillesen (Copenhagen, Denmark). This issue has
been controversial for many years, and in our part of the world, this
is not an option. We just heard from Australia that they are working
on the Tamaris project, which is just another option of treatment
for these patients who cannot be reconstructed. Would it be
possible to do a double-blind trial? I can easily imagine some
problems with how to have a placebo injection, but would it be
possible?
Dr Vishnu Motukuru. That would be tough. The TAG
study was published, we have the first part of the study; it was a
double-blind plan in which one group had saline injected and the
other had stem cells injected. But in the immune setup, it is not
going to be easy. The second thing you need to bear in mind is the
whole cost of this procedure, it is probably around $200 to $300,
and even this had to be funded in total.
Dr Krish Soundararajan (Philadelphia, Pa). In an era where
surgeons seek invasive therapy, it is refreshing to see your work on
nonsurgical management of critical limb ischemia. I have two
questions. The first one is would the stem cell therapy have any
different outcome if you had applied it in ischemia due to athero-
sclerosis rather than Buerger’s disease? Is there any reason why you
chose to confine the therapy to Buerger’s disease?
The second question is with regards to the cost factor and my
understanding that many patients in India may not be able to
afford therapies to improve lifestyle in occlusive disease. How do
you see stem cell therapy helping an average laborer in India?
Would this be a technology which is beyond their means?
DrMotukuru. Firstly, it is still quite controversial. So we just
wanted to apply this, because it is being done for the first time in
India, so we wanted to play safe. So that is the reason we excluded
diabetics and we offered this only to patients in whom nothing else
is possible. Probably in our older patients and patients with ath-
erosclerosis, there are other alternatives which can be tried. But this
was offered only to a specific subset of nonclassical Buerger’s in
whom everything else has been tried. So that is the reason we
specifically selected this subset wherein there is no option at all
other than an amputation.
Dr Soundararajan. Does that mean if you had a patient with
ischemia due to atherosclerosis who did not have any other optionsDr Motukuru. I doubt it, because we were basically looking
at people who are young, who are extremely healthy, and who
could probably tolerate any complication. So a person with ad-
vanced atherosclerosis, your morbidity/mortality would go up
given the nature of the disease.
Dr Chris Liapis (Athens, Greece). Most of the times patients
with Buerger’s disease have lesions in the distal arteries, like digital
arteries. Why do you think that injecting the calf area is going to
improve the situation in the obstructed distal arteries?
DrMotukuru. Because this was the first series, we injected all
the patients into the calf muscles. But the last five cases, we were
also injecting the stem cells into the foot. But because we don’t
have a 6-month follow-up, I haven’t presented those.
Dr Enrico Ascher (Brooklyn, NY). I know of at least three
stem cell studies investigating the potential for limb salvage. In our
study we agreed to inject the stem cells along the course of tibial
vessels. Do you think that this method better promotes angiogen-
esis?
Dr Motukuru. I am not aware of it, sir. But we started
injecting in the foot. But as far as the results are concerned, I have
no idea.
Dr Gregorio Sicard (St. Louis, Mo). These patients, obvi-
ously, all of them are very heavy smokers. And did you look, even
though it is a small number of patients, how many of these patients
continued their smoking habits? Because I think that is going to
muddy the results.
And the second question, one of the therapies that is being
looked at, obviously, in multiple institutions across the world, is
rather than obtaining the stem cells from the bone marrow is to use
granulocyte stimulation factors or certain factors that promote the
recruitment of stem cells from the bone marrow to the site of the
ischemia. Have you looked at that in India?
DrMotukuru. We haven’t, sir, because there were a couple of
papers which said granulocyte-stimulated factors helped, but then
there were a couple of papers that said it doesn’t help. And
secondly, one of the limitations of the study was we did give them
a strong counseling, but we did not do urine creatinine assay levels
to really assess whether they were actually smoking or not smoking;
and hence, we couldn’t really assess the impact of our counseling
on the results, purely because of financial constraints.
